Pharmacy Website
Clinic Website

Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes

Calculators  Oncology
Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes is quick and practical tool utilized for the prognosis of cancer by using the serum biomarkers
CRP ≤10 mg/L 0
CRP >10 mg/L 2
Albumin <3.5 g/dL (35 g/L) 0
Albumin ≥3.5 g/dL (35 g/L) 1


Measured Factor
Modified Glasgow Prognostic Score
Measured Factor Disease
  • Cancer
Measured Factor Detail
Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes is used to provide the improved cancer prognosis by using the serum biomarkers. It is employed to decrease the significant worse outcome and complication. The calculation takes into account patient features such as level of CRP and albumin.
Body System
Measured Factor Low Impact
  • Score 0 illustrates good prognosis
Measured Factor High Impact
  • Score 1 indicates intermediate prognosis
  • Score 2 illustrates poor prognosis

Result Interpretation

Ranges Ranges
  • Critical High: 200%
  • Normal: 1
  • Normal Adult Male: 100%
  • Normal Adult Female: 100%
  • Normal Geriatric Male: 100%
  • Normal Geriatric Female: 100%
Result High Conditions
  • Cancer
False Positive
  • Antibodies are the main reason for false-positive outcomes
References: 2
Test Limitations
It is related with treatment toxicity, poor nutritional, reduced treatment response
References: 3


Study Validation 1
The authors investigated the relationships between the prognostic impact of mGPS and mGPS and clinical variables in patients with advanced cancer initial palliative care (PC). mGPS of 0 was assigned to 79.7% of patient, mGPS of 1 was assigned to 6.8% of patient, and mGPS of 2 was assigned to 13.5% of the patients, respectively. A positive association between primary lung cancer with P = 0.021, hepatic metastasis of P = 0.004, PC only of P < 0.001, higher systemic inflammation of mGPS 1/2, and lower Karnofsky Performance Status of P < 0.001 was found. Median overall survival was 5.7, 3 and 1 months for mGPS of 0, 1, and 2, respectively. mGPS remained an independent prognostic marker, after multivariate analyses. It is concluded that Systemic inflammatory response is related with primary lung cancers, a low functional status, and hepatic metastasis tumors . When started with Palliative care, clinical utility implications should be present in mGPS defination, by identifying 3 groups of patients with an advanced cancer patients having distinct survival outcomes.
References: 4
Study Validation 2
The aim of the study was to elucidate a significance of GPS in colorectal carcinoma. The investigation is carried out in 272 patients with colorectal carcinoma. Survival of GPS 1 patients was notably worse than that of GPS 0 patients, and survival of GPS 2 patients was crucially worse than that of GPS 1 patients. Similarly, with the mGPS. Multivariate analysis demonstrated that tumor stage (P= 0.004) as well as venous invasion (P = 0.011) and GPS (P < 0.0001) were factors independently related with worse prognosis. Both GPS and mGPS could be applied in colorectal carcinoma as prognostic indicators.
References: 5
Study Validation 3
The study aims to validate the ability of the mGPS to predict metastasis in localized renal cell carcinoma (RCC). Results are as Out of the 129 patients, 23.3% of patient developed metastases. After tumor & patient characteristics in multivariate analysis only mGPS was shown to be significantly associated with RFS. It is concluded that mGPS is a strong predictor of metastasis for localized RCC. Clinicians can consider mGPS as an adjunct to examine high-risk patients for patient counseling.
References: 6
Study Additional 1
This study compares the important prognostic factors in advanced lung cancer. A total of 390 patients with advanced lung cancer were recruited with stage IV non-small cell, out of them 341 were male. The median age was around 66 years. The median survival was of 7.8 months. On multivariate analysis only performance status and mGPS predicted survival (p<0.001). 99% to 74% of survival at 3 months and 99% to 71% (mGPS2) using mGPS. In combination, survival ranged from 99% (mGPS 0) to 33% (mGPS 2). It is concluded that the mGPS and Performance status are of higher level prognostic factors in the advanced lung cancer.
References: 3
Study Additional 2
The aim of the study was to compare the prognostic value of modified Glasgow Prognostic Score, Neutrophil Lymphocyte Ratio , Platelet Lymphocyte Ratio, Prognostic Index, Prognostic Nutritional Index. As, all of these scores are associated with cancer specific survival. 4417 were cancer deaths out of 5163 deaths. The median time to diagnosis from blood sampling was 1.7 months. An increased PI, mGPS,  PNI, PLR, NLR were predictive of a reduced cancer specific survival. These were independent of sex, age and tumour site. The study concludes that systemic inflammation-based scores (mGPS and PI) have prognostic value in cancer specific survival. Based on the present results, the mGPS should be present in the routine assessment of cancer patients.
References: 7


  1. Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104(4):726-34.
  2. Jiang L, Jiang S, Lin Y, et al. Modified inflammation-based score as an independent malignant predictor in patients with pulmonary focal ground-glass opacity: a propensity score matching analysis. Sci Rep. 2016;6:19105.
  3. Simmons CP, Koinis F, Fallon MT, Fearon KC, Bowden J, Solheim TS, et al. Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors. Lung Cancer. 2015;88(3):304-9.
  4. Pantano Nde P, Paiva BS, Hui D, Paiva CE. Validation of the Modified Glasgow Prognostic Score in Advanced Cancer Patients Receiving Palliative Care. J Pain Symptom Manage. 2016;51(2):270-7.
  5. Nozoe T, Iguchi T, Egashira A, Adachi E, Matsukuma A, Ezaki T. Significance of modified Glasgow prognostic score as a useful indicator for prognosis of patients with gastric carcinoma. Am J Surg. 2011;201(2):186-91.
  6. Tai CG, Johnson TV, Abbasi A, Herrell L, Harris WB, Kucuk O, et al. External validation of the modified Glasgow prognostic score for renal cancer. Indian J Urol. 2014;30(1):33-7.
  7. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47(17):2633-41.

Sign Up